AQP4 (D1F8E) XP® Rabbit mAb (BSA and Azide Free) #39374
- WB
- IHC
- IF
To Purchase # 39374
| Cat. # | Size | Qty. | Price |
|---|---|---|---|
| 39374SF | 100 µg | $843 |
Supporting Data
| REACTIVITY | H M R |
| SENSITIVITY | Endogenous |
| MW (kDa) | 28 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IHC-Immunohistochemistry
- IF-Immunofluorescence
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
- Related Products
Product Information
Product Usage Information
This formulation is ideal for use with technologies requiring specialized or custom antibody labeling, including fluorophores, metals, lanthanides, and oligonucleotides. It is not recommended for ChIP, ChIP-seq, CUT&RUN or CUT&Tag assays. If you require a carrier free formulation for chromatin profiling, please contact us. Optimal dilutions/concentrations should be determined by the end user.
BSA and Azide Free antibodies are quality control tested by size exclusion chromatography (SEC) to determine antibody integrity.
Formulation
For standard formulation of this product see product #59678
Storage
Specificity / Sensitivity
Species Reactivity:
Source / Purification
Background
AQP4 is expressed in brain cells, including neurons, but enriched in astrocytes, as well as in the peripheral nervous system (4,7). AQP4 influences synaptic plasticity and the lack of this protein in the brain may cause memory and learning impairment via glutamate transporter 1 (GLT1) in Alzheimer's disease (8,9,10). It's suggested that AQP4 could play a role in the clearance of β-amyloid, and it may influence the transport of potassium and calcium in Alzheimer's disease (8,9). In Parkinson's disease, the lack of AQP4 results in an increased susceptibility of neurons from the substantia nigra and the ventral tegmental area for MPTP (11).
- Takata, K. et al. (2004) Prog Histochem Cytochem 39, 1-83.
- Echevarría, M. and Ilundáin, A.A. (1998) J Physiol Biochem 54, 107-18.
- Gomes, A. et al. (2018) Front Chem 6, 238.
- Xu, M. et al. (2017) Adv Exp Med Biol 969, 81-103.
- Kobayashi, H. et al. (2004) J Pharmacol Sci 96, 264-70.
- Meli, R. et al. (2018) Front Physiol 9, 101.
- Ishibashi, K. et al. (1998) Biochem Biophys Res Commun 244, 268-74.
- Hubbard, J.A. et al. (2018) Brain Res Bull 136, 118-129.
- Lan, Y.L. et al. (2016) Neural Plast 2016, 4626593.
- Lan, Y.L. et al. (2016) Mol Neurobiol 53, 5300-9.
- Zhang, J. et al. (2016) Neurosci Lett 614, 7-15.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.